|Mr. Fuad El-Hibri||Founder & Exec. Chairman||1.2M||9.68M||1958|
|Mr. Robert G. Kramer||CEO, Pres & Exec. Director||2.13M||N/A||1957|
|Mr. Richard S. Lindahl||Exec. VP, CFO & Treasurer||1.02M||N/A||1964|
|Mr. Adam R. Havey||Exec. VP & COO||1M||1.44M||1971|
|Mr. Atul Saran||Exec. VP of Corp. Devel. & Ext. Affairs and Gen. Counsel||983.57k||N/A||1973|
|Mr. Howard Anderson||Sr. VP & Chief Information Officer||N/A||N/A||N/A|
|Mr. Robert G. Burrows||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Lynn Kieffer||VP of Corp. Communications||N/A||N/A||N/A|
|Ms. Nina DeLorenzo||Sr. VP of Global Communications & Public Affairs||N/A||N/A||N/A|
|Ms. Katherine Strei||Exec. VP of HR & Chief HR Officer||N/A||N/A||1962|
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; and Trobigard, a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG for the treatment of SARS-CoV-2; FLU-IGIV for the treatment of seasonal influenza A virus; AV7909, an anthrax vaccine candidate; CHIKV VLP, a chikungunya virus VLP vaccine; ZIKV-IG, a zika therapeutic candidate; Shigella-ETEC, a shigella vaccine expressing ETEC antigens; EBS-LASV, a vector vaccine for Lassa fever; UNI-FLU, a universal influenza vaccine; rVSV-Marburg, a vector vaccine for treatment of Marburg virus disease; rVSV-Sudan, a vector vaccine for treatment of Sudan virus disease; DAT, a diphtheria antitoxin; Ricin-IG, a ricin antitoxin; and Pan-Ebola, a Ebola/Sudan monoclonal. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Emergent BioSolutions Inc.’s ISS governance QualityScore as of 1 July 2021 is 6. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 7; Compensation: 2.